Anti-cyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis: Bayes clears the haze

Annals of Internal Medicine

Volumn 146, Issue 11, 2007, Pages 816-817

  Finckh, Axel ^a   Liang, Matthew H ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HLA DR4 ANTIGEN; RHEUMATOID FACTOR; AUTOANTIBODY; BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; UNCLASSIFIED DRUG;

CLINICAL FEATURE; CLINICAL TRIAL; DELAYED DIAGNOSIS; DISEASE COURSE; EDITORIAL; GOLD STANDARD; HUMAN; LABORATORY TEST; MEDICAL DECISION MAKING; META ANALYSIS; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; BLOOD; IMMUNOLOGY; NOTE;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; PEPTIDES, CYCLIC; RHEUMATOID FACTOR; SENSITIVITY AND SPECIFICITY;

EID: 34250685741     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-146-11-200706050-00011     Document Type: Editorial

References (20)